Obesity — defined as a BMI over 30 — affects over 42% of American adults and drives type 2 diabetes, hypertension, sleep apnea, cardiovascular disease, and cancer risk. At Viva Medical Center, we treat obesity as the chronic condition it is, with science-based interventions including GLP-1 medications, lifestyle programs, and ongoing medical supervision.
Our Weight Loss Approach
- Medical evaluation: labs, metabolic assessment, comorbidity review
- Personalized nutrition plan (Mediterranean, low-glycemic, or calorie-controlled)
- Physical activity prescription
- GLP-1 medication evaluation: semaglutide (Wegovy/Ozempic) or tirzepatide (Zepbound/Mounjaro)
- Monthly check-ins and dose titration
- Behavioral support and goal tracking
GLP-1 Medications We Prescribe
Semaglutide (Wegovy for weight loss, Ozempic for diabetes) produces average 15% body weight reduction. Tirzepatide (Zepbound for weight loss, Mounjaro for diabetes) achieves up to 21% weight reduction in clinical trials. Both are once-weekly injectables.
Who Is a Candidate
- BMI ≥ 30 (any weight-related condition)
- BMI ≥ 27 with hypertension, diabetes, or sleep apnea
- Prior weight loss attempts without sustainable results
- Desire for medically supervised, evidence-based program